Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

Learn how Novartis is working with chronic obstructive pulmonary disease (COPD) patients to develop digital health technologies that help them find their “new normal.”

Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR) and Vas Narasimhan, Head of Global Drug Development and Chief Medical Officer, share their outlook for innovation in 2017.

Novartis internships help build research capabilities in developing countries.

The Co-Creating Impact Summit 2020 was a succesful event with important steps on our work of improving our impact on the society and the planet.

Health experts from around the world met November 29 to discuss ways to tackle an emerging crisis.

Novartis reaffirms commitment to fighting malaria and recognizes the dedication of our people and partners.